XSHE
002365
Market cap577mUSD
Oct 09, Last price
13.47CNY
1D
2.67%
1Q
28.78%
Jan 2017
-19.34%
IPO
-8.05%
Name
Qianjiang Yongan Pharmaceutical Co Ltd
Chart & performance
P/E
176.47
P/S
5.07
EPS
0.08
Div yield, %
0.76%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
-12.93%
Revenues
783m
-6.63%
Net income
22m
-63.58%
CFO
139m
+31.57%
Dividend
Jun 11, 20260.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.
Key people
Yong Chen
Chairman of the Board · since 2024
Rengui Hong
General Manager, Director · since 2024
Zidi Chen
Executive Deputy General Manager, Director · since 2024
Xiquan Fang
Deputy General Manager · since 2024
Zhihua Wang
Deputy General Manager · since 2024
Wei Ye
Deputy General Manager · since 2024
Yonghong Deng
Senior Management · since 2024
Wei Dong
Senior Management · since 2024
Shaobo Li
Senior Management · since 2024
Qiong Wu
Senior Management · since 2024
Shengjie Xiong
Chief Financial Officer, Secretary of the Board · since 2024
Xiaohua Guo
Independent Director · since 2025
Bing Zhang
Independent Director · since 2024
Independent Director · since 2024
Headquarters & legal address
湖北省潜江经济开发区广泽大道2号
荆州市, HB 433100
CN
荆州市, HB 433100
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||